Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The United Laboratories International Holdings ( (HK:3933) ) just unveiled an announcement.
The United Laboratories International Holdings has received approval from China’s National Medical Products Administration to begin clinical trials of UBT251 Injection for treating moderate to severe obstructive sleep apnea associated with obesity. UBT251 is a class 1 innovative, chemically synthesized triple agonist acting on GLP-1, GIP and glucagon receptors, designed to lower blood glucose and curb weight gain, and is described as the first GLP-1R/GIPR/GCGR triple agonist of its kind in China. The drug is already in Phase II trials domestically for overweight or obesity, type 2 diabetes, metabolic-associated steatohepatitis and chronic kidney disease, and the new OSA indication strengthens the company’s positioning as a key R&D player in multi-target metabolic therapies, potentially enhancing its competitiveness and long-term value for shareholders if clinical outcomes are successful.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a biopharmaceutical company engaged in the research and development of innovative drugs, including peptide-based therapies targeting metabolic and chronic diseases. Through its wholly owned unit The United Bio-Technology (Hengqin) Co., Ltd., the group focuses on advanced treatments for obesity, diabetes, obstructive sleep apnea and related metabolic conditions in the Chinese market.
Average Trading Volume: 9,368,295
Technical Sentiment Signal: Buy
Current Market Cap: HK$23.48B
See more insights into 3933 stock on TipRanks’ Stock Analysis page.